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CASE REPORT
Two cases of relapsed HIV-associated 
visceral leishmaniasis successfully treated 
with combination therapy
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Abstract 
Background: The management of visceral leishmaniasis (VL) in HIV-infected patients is often complex with patients 
experiencing higher mortality rates, more toxic side effects and a higher possibility of treatment failure and relapse 
than HIV-negative individuals with VL.
Case presentation: We report on successful salvage therapy in two HIV-infected patients suffering with dissemi-
nated cutaneous and visceral leishmaniasis, recalcitrant to therapy with liposomal amphotericin B. After the employ-
ment of combination anti-leishmanial treatment, parasite genomes were not detectable up to the last follow up visit, 
57 and 78 weeks after treatment onset, respectively. CD4+ lymphocyte counts fluctuated over time, but were gener-
ally higher than counts detected at treatment onset, which likely contributed to protection against VL relapse.
Conclusions: Results achieved with the anti-leishmanial combination treatment were promising, but are based on 
only two patients. Future investigation is necessary to confirm the efficacy of this salvage therapy in sustaining the 
immunological response and control of VL.
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Background
Visceral leishmaniasis (VL) and HIV co-infection is 
common in tropical areas and can occur in southern 
European countries [1]. Concerning the WHO Euro-
pean Region, the estimated annual incidence of VL/HIV 
co-infection is around 1100–1900 cases/year [2]. The 
Leishmania-HIV interplay at the cellular and molecular 
level appears to affect the course of infection for both 
pathogens [3] as VL hampers the immunological com-
petence of HIV-positive patients, while HIV-infected 
patients with VL exhibit reduced anti-leishmanial drug 
response, frequent relapses and higher mortality rates 
than HIV-negative individuals [1, 2]. A combination 
anti-leishmanial therapy might be considered in HIV/
VL co-infection, especially for HIV patients with refrac-
tory cases of VL [4, 5]. Nevertheless, a valuable multidrug 
therapy and optimal treatment duration have yet to be 
established.
Case description
We report on two patients with Leishmania infantum-
induced VL and HIV-1 co-infection who received an 
extended course of a salvage therapy (anti-leishmanial 
combination treatment, cAnti-Leish) in addition to 
antiretroviral therapy (ART). The rationale behind mul-
tidrug therapy against Leishmania was to increase drug 
activity with compounds targeting different pathways 
of the parasite metabolism, ultimately preventing the 
emergence of drug resistance. Drugs with distinct activ-
ity against Leishmania were used, including those target-
ing ergosterol biosynthesis (liposomal amphotericin B 
[L-amB] and fluconazole) and cell membrane integrity 
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(L-amB), modulating surface signaling pathways (miltefo-
sine) interfering with the purine salvage pathway (allopu-
rinol) and hindering DNA synthesis at mitochondrial 
level (pentamidine) [6, 7]. Furthermore, HIV-1 protease 
inhibitors (PI) were employed as adjunctive anti-leishma-
nial therapy for HIV-associated VL [8]. In fact, in  vitro 
[9] and in vivo [10] evidence suggests that high dose PI 
hamper Leishmania replication and exhibit synergistic 
effect with L-amB and miltefosine [10].
Our regimen resulted in good control of VL and HIV-1 
infection in both patients, whereas previously admin-
istered conventional monotherapy with L-amB (dosage 
regimen of 4 mg/kg on days 1–5, 10, 17, 24, 31 and 38, for 
a total dose of 40 mg/kg) followed by secondary prophy-
laxis (3  mg/kg every 4  weeks) did not prevent multiple 
VL relapses. The study was conducted in accordance with 
the Declaration of Helsinki. Written informed consent 
was obtained from the patients included in the study.
Case 1 was a 55-year-old man who presented at the 
Unit of Infectious Diseases, Forlì Hospital (northeastern 
Italy) with a 4-year history of HIV infection and a 2-year 
history of disseminated cutaneous leishmaniasis. Despite 
being under secondary prophylaxis with L-amB, severe 
gastroenterological disease caused by Leishmania was 
discovered. Case 2 was a 50-year old HIV-positive man 
who presented with a 6-year history of HIV infection and 
a 3-year history of disseminated cutaneous leishmaniasis 
and VL, recalcitrant to therapy with L-amB.
Leishmanial DNA was detected by real-time PCR in the 
peripheral blood, bone marrow aspirates and skin biop-
sies of both patients (Fig. 1 and not shown). Additionally, 
stomach and colon biopsies from Case 1 tested posi-
tive for leishmanial DNA. In both cases, bone marrow 
showed high levels of parasitemia (around 10E6 parasite 
genomes/mL), while lower levels (around 10E2–10E3 
parasite genomes/mL) were detected in peripheral blood 
(Fig. 1). Patients exhibited a CD4+ count of 225 cells/μL 
and 170 cells/μL before cAnti-Leish, Case 1 and Case 2, 
respectively. The nadir CD4 cell count was 120 cells/μL 
and 143 cells/μL, Case 1 and Case 2, respectively.
High and intermittent doses of L-amB in 5% dextrose 
i.v. infusion over 4  h (4  mg/kg/day on days 1–5, 10, 17, 
24, 32 and 38) were administered for VL treatment [1, 
4]. The patients also received concomitant miltefosine 
(50 mg three times/day for 28 days), allopurinol (300 mg 
four times daily for 15  days) and de-escalating doses of 
fluconazole (from 600 to 400 mg/day for 28 days). Since 
PI can also be considered an adjunctive anti-leishma-
nial therapy, ART was modified by adding a boosted PI 
treatment, including darunavir (800  mg/day) and rito-
navir (100  mg/day) in Case 1 and atazanavir (300  mg/
day) and ritonavir (100  mg/day) in Case 2, respectively, 
while the backbone therapy included lamivudine 300 mg/
day and tenofovir disoproxil fumarate (245  mg/day) in 
both patients. Once remission was achieved, includ-
ing resolution of fever, remarkable improvement of the 
patient’s general condition, regression of splenomegaly 
and amelioration of laboratory parameters, a mainte-
nance treatment was instituted for 12 weeks with L-AmB 
(2–3  mg/kg every 3  weeks), miltefosine (50  mg three 
times weekly), allopurinol (300 mg twice daily), flucona-
zole (400  mg/day) and pentamidine aerosol (300  mg 
twice a month for the first 2 months, then once a month 
for 6  months). One week after cAnti-Leish onset, there 
was a significant decline in peripheral blood parasitemia 
(Fig. 1); we observed a good correlation between clinical 
outcome and blood parasite burden. To consolidate activ-
ity against potentially residual parasites, a second cycle 
of the initial and maintenance therapy was given to both 
patients (Case 1 only received 2 mg/kg L-Amb in the sec-
ond cycle). Secondary prophylaxis with L-Amb (2–3 mg/
kg every 3–4  weeks) was subsequently administered. 
Parasite genomes were not detectable over time up to 
the last follow-up visit (Week 57 and Week 78 for Case 1 
and Case 2, respectively). CD4+ lymphocyte counts fluc-
tuated over time, but were generally higher than counts 
detected at treatment onset, which likely contributed to 
protection against VL relapse.
Discussion and conclusions
It has been suggested that combined drug regimens 
are the best option for VL/HIV co-infected patients by 
increasing drug efficacy, reducing toxicity and hampering 
the emergence of resistance [4, 5]. So far, the best combi-
nation therapy appears to be L-amB plus miltefosine due 
to the observed synergism between the two compounds 
in vitro and in animal models [11]. Furthermore, a com-
bination regimen consisting of L-amB and miltefosine 
was employed in VL/HIV co-infected patients in a pilot 
study performed by Médecin Sans Frontières in Ethio-
pia [12] as well as in 120 VL/HIV co-infected patients in 
India [13], showing encouraging results.
Here, the employment of L-amB and miltefosine was 
associated to other drugs with anti-leishmanial effects, 
including fluconazole, allopurinol and pentamidine. 
Results achieved with cAnti-Leish were promising, but 
are based on only two patients. Thus, future investiga-
tion is necessary to confirm the efficacy of this salvage 
therapy. Furthermore, the potentially synergistic role of 
cAnti-Leish and a PI-based ART regimen in sustaining 
the immunological response and control of VL should 
be further explored as recent evidence suggests that both 
CD4+ count and circulating Leishmania DNA contribute 
to prognosis in HIV/VL co-infection [14].
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Fig. 1 Time course of parasitological and immunological parameters upon combined anti-leishmanial treatment in Case 1 (a) and Case 2 (b). 
Parasitemia (red circles) was measured by quantitative real-time PCR (qPCR) before and after anti-leishmanial combination (cAnti-Leish) treatment. 
Also shown is the CD4+ cell count in peripheral blood (empty squares; normal range: 500–1500 cells/μL). HIV RNA was < 40 copies/mL in Case 
1 and Case 2 throughout the study as tested by the Veris DxN HIV-1 assay (Beckman Coulter, Brea, CA USA). Leishmanial DNA was detected in 
peripheral blood by two distinct real-time (RT) PCR assays, amplifying segments of the small-subunit ribosomal RNA gene and the kinetoplast DNA 
(kDNA) [15]. Samples testing positive for parasitic DNA were then quantified by RT-PCR for the single copy polymerase gene (pol) of Leishmania 
[16]. The detection limit was 0.00005 parasite/reaction for kDNA RT-PCR and 1 parasite/reaction for pol RT-PCR. Leishmania typing was performed 
by hsp70 PCR [17] and L. infantum was identified in both patients. ▲: Parasitemia was quantified in bone marrow aspirates within one week before 
cAnti-Leish onset
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